Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Mathieu Roche discusses the role of identity in digital advertising performance, emphasizing transparent data collection and ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

June 6, 2025 Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain ...